Clinical Proof-of-concept of a Novel Platform Utilizing Biopsy-derived Live Single Cells, Phenotypic Biomarkers, and Machine Learning Toward a Precision Risk Stratification Test for Prostate Cancer Grade Groups 1 and 2 (Gleason 3 + 3 and 3 + 4).

MLA

Albala, David, et al. “Clinical Proof-of-Concept of a Novel Platform Utilizing Biopsy-Derived Live Single Cells, Phenotypic Biomarkers, and Machine Learning Toward a Precision Risk Stratification Test for Prostate Cancer Grade Groups 1 and 2 (Gleason 3 + 3 and 3 + 4).” Urology, vol. 124, Feb. 2019, pp. 198–206. EBSCOhost, https://doi.org/10.1016/j.urology.2018.09.032.

APA

Albala, D., Manak, M. S., Varsanik, J. S., Rashid, H. H., Mouraviev, V., Zappala, S. M., Ette, E., Kella, N., Rieger-Christ, K. M., Sant, G. R., & Chander, A. C. (2019). Clinical Proof-of-concept of a Novel Platform Utilizing Biopsy-derived Live Single Cells, Phenotypic Biomarkers, and Machine Learning Toward a Precision Risk Stratification Test for Prostate Cancer Grade Groups 1 and 2 (Gleason 3 + 3 and 3 + 4). Urology, 124, 198–206. https://doi.org/10.1016/j.urology.2018.09.032

Chicago

Albala, David, Michael S Manak, Jonathan S Varsanik, Hani H Rashid, Vladimir Mouraviev, Stephen M Zappala, Ene Ette, et al. 2019. “Clinical Proof-of-Concept of a Novel Platform Utilizing Biopsy-Derived Live Single Cells, Phenotypic Biomarkers, and Machine Learning Toward a Precision Risk Stratification Test for Prostate Cancer Grade Groups 1 and 2 (Gleason 3 + 3 and 3 + 4).” Urology 124 (February): 198–206. doi:10.1016/j.urology.2018.09.032.